{"id":56303,"date":"2026-02-04T23:09:42","date_gmt":"2026-02-04T15:09:42","guid":{"rendered":"https:\/\/flcube.com\/?p=56303"},"modified":"2026-02-04T23:09:43","modified_gmt":"2026-02-04T15:09:43","slug":"hualan-biologicals-hl08-glp-1-drug-gets-nmpa-nod-for-obesity-trial","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56303","title":{"rendered":"Hualan Biological&#8217;s HL08 GLP-1 Drug Gets NMPA Nod for Obesity Trial"},"content":{"rendered":"\n<p><strong>Hualan Biological Engineering Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/002007:SHE\">SHE: 002007<\/a>) announced that the <strong>National Medical Products Administration (NMPA)<\/strong> has approved a clinical trial for <strong>HL08<\/strong>, its next\u2011generation <strong>GLP\u20111 receptor agonist<\/strong>, for a new indication in <strong>weight control for obese patients<\/strong>. The fusion protein design extends half\u2011life while retaining Exendin\u20114&#8217;s physiological functions.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone-amp-drug-profile\">Regulatory Milestone &amp; Drug Profile<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Hualan Biological Engineering Inc. (002007.SZ)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>HL08 (recombinant Exendin\u20114\u2011Fc fusion protein)<\/td><\/tr><tr><td><strong>Approval<\/strong><\/td><td>NMPA clinical trial authorization<\/td><\/tr><tr><td><strong>New Indication<\/strong><\/td><td>Weight control in obese patients<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>GLP\u20111 receptor agonist<\/td><\/tr><tr><td><strong>Design<\/strong><\/td><td>Exendin\u20114 fused with IgG2 Fc fragment via specific linker peptide<\/td><\/tr><tr><td><strong>Key Advantage<\/strong><\/td><td>Extended biological half\u2011life, enhanced dosing convenience<\/td><\/tr><tr><td><strong>Preclinical Data<\/strong><\/td><td>Demonstrated weight loss, lipid metabolism improvement, \u03b2\u2011cell protection<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-mechanism-of-action-amp-clinical-benefits\">Mechanism of Action &amp; Clinical Benefits<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Extended Half\u2011Life:<\/strong> Fusion with IgG2 Fc fragment significantly prolongs biological half\u2011life while retaining Exendin\u20114\u2019s natural physiological functions<\/li>\n\n\n\n<li><strong>Glucose\u2011Dependent Action:<\/strong> Achieves glucose\u2011lowering effects in a glucose concentration\u2011dependent manner<\/li>\n\n\n\n<li><strong>Multiple Metabolic Effects:<\/strong> Promotes insulin secretion, inhibits glucagon secretion, delays gastric emptying, increases satiety<\/li>\n\n\n\n<li><strong>\u03b2\u2011Cell Protection:<\/strong> Protects islet \u03b2\u2011cell function, suitable for type 2 diabetes patients with metabolic syndrome<\/li>\n\n\n\n<li><strong>Metabolic Benefits:<\/strong> Significant effects on weight loss and lipid metabolism improvement<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-commercial-outlook\">Market Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Obesity Market:<\/strong> Valued at <strong>\u00a550\u202fbillion<\/strong> (~US$7\u202fbillion) in 2025, growing at <strong>25% CAGR<\/strong> driven by GLP\u20111 therapies<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Competes with <strong>semaglutide (Novo Nordisk)<\/strong> and <strong>tirzepatide (Eli Lilly)<\/strong>; HL08\u2019s extended half\u2011life offers dosing convenience<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Analysts project <strong>\u00a52\u20133\u202fbillion<\/strong> (US$280\u2013420\u202fmillion) peak annual sales by 2028 if approved for obesity<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> Expands Hualan\u2019s metabolic disease franchise beyond diabetes; positions company in high\u2011growth obesity segment<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> Phase I\/II obesity trial initiation expected <strong>Q2\u202f2026<\/strong>; potential for expedited NMPA review given unmet medical need<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, regulatory pathways, and revenue projections for HL08. Actual results may differ due to clinical trial outcomes, competitive dynamics, and NMPA review processes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/\u534e\u5170\u751f\u7269\uff1a\u5173\u4e8e\u6536\u5230\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u534e\u5170\u751f\u7269\uff1a\u5173\u4e8e\u6536\u5230\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-d4b81890-d586-4083-b31d-6a60a212a262\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/\u534e\u5170\u751f\u7269\uff1a\u5173\u4e8e\u6536\u5230\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.pdf\">\u534e\u5170\u751f\u7269\uff1a\u5173\u4e8e\u6536\u5230\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/\u534e\u5170\u751f\u7269\uff1a\u5173\u4e8e\u6536\u5230\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-d4b81890-d586-4083-b31d-6a60a212a262\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Hualan Biological Engineering Inc. (SHE: 002007) announced that the National Medical Products Administration (NMPA) has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,4283,86,1564],"class_list":["post-56303","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-hualan-biological-engineering","tag-obesity","tag-she-002007"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hualan Biological&#039;s HL08 GLP-1 Drug Gets NMPA Nod for Obesity Trial - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hualan Biological Engineering Inc. (SHE: 002007) announced that the National Medical Products Administration (NMPA) has approved a clinical trial for HL08, its next\u2011generation GLP\u20111 receptor agonist, for a new indication in weight control for obese patients. The fusion protein design extends half\u2011life while retaining Exendin\u20114&#039;s physiological functions.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56303\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hualan Biological&#039;s HL08 GLP-1 Drug Gets NMPA Nod for Obesity Trial\" \/>\n<meta property=\"og:description\" content=\"Hualan Biological Engineering Inc. (SHE: 002007) announced that the National Medical Products Administration (NMPA) has approved a clinical trial for HL08, its next\u2011generation GLP\u20111 receptor agonist, for a new indication in weight control for obese patients. The fusion protein design extends half\u2011life while retaining Exendin\u20114&#039;s physiological functions.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56303\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-04T15:09:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-04T15:09:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56303#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56303\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hualan Biological&#8217;s HL08 GLP-1 Drug Gets NMPA Nod for Obesity Trial\",\"datePublished\":\"2026-02-04T15:09:42+00:00\",\"dateModified\":\"2026-02-04T15:09:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56303\"},\"wordCount\":336,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Hualan Biological Engineering\",\"Obesity\",\"SHE: 002007\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56303#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56303\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56303\",\"name\":\"Hualan Biological's HL08 GLP-1 Drug Gets NMPA Nod for Obesity Trial - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-04T15:09:42+00:00\",\"dateModified\":\"2026-02-04T15:09:43+00:00\",\"description\":\"Hualan Biological Engineering Inc. (SHE: 002007) announced that the National Medical Products Administration (NMPA) has approved a clinical trial for HL08, its next\u2011generation GLP\u20111 receptor agonist, for a new indication in weight control for obese patients. The fusion protein design extends half\u2011life while retaining Exendin\u20114's physiological functions.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56303#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56303\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56303#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hualan Biological&#8217;s HL08 GLP-1 Drug Gets NMPA Nod for Obesity Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hualan Biological's HL08 GLP-1 Drug Gets NMPA Nod for Obesity Trial - Insight, China&#039;s Pharmaceutical Industry","description":"Hualan Biological Engineering Inc. (SHE: 002007) announced that the National Medical Products Administration (NMPA) has approved a clinical trial for HL08, its next\u2011generation GLP\u20111 receptor agonist, for a new indication in weight control for obese patients. The fusion protein design extends half\u2011life while retaining Exendin\u20114's physiological functions.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56303","og_locale":"en_US","og_type":"article","og_title":"Hualan Biological's HL08 GLP-1 Drug Gets NMPA Nod for Obesity Trial","og_description":"Hualan Biological Engineering Inc. (SHE: 002007) announced that the National Medical Products Administration (NMPA) has approved a clinical trial for HL08, its next\u2011generation GLP\u20111 receptor agonist, for a new indication in weight control for obese patients. The fusion protein design extends half\u2011life while retaining Exendin\u20114's physiological functions.","og_url":"https:\/\/flcube.com\/?p=56303","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-04T15:09:42+00:00","article_modified_time":"2026-02-04T15:09:43+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56303#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56303"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hualan Biological&#8217;s HL08 GLP-1 Drug Gets NMPA Nod for Obesity Trial","datePublished":"2026-02-04T15:09:42+00:00","dateModified":"2026-02-04T15:09:43+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56303"},"wordCount":336,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","Hualan Biological Engineering","Obesity","SHE: 002007"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56303#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56303","url":"https:\/\/flcube.com\/?p=56303","name":"Hualan Biological's HL08 GLP-1 Drug Gets NMPA Nod for Obesity Trial - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-04T15:09:42+00:00","dateModified":"2026-02-04T15:09:43+00:00","description":"Hualan Biological Engineering Inc. (SHE: 002007) announced that the National Medical Products Administration (NMPA) has approved a clinical trial for HL08, its next\u2011generation GLP\u20111 receptor agonist, for a new indication in weight control for obese patients. The fusion protein design extends half\u2011life while retaining Exendin\u20114's physiological functions.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56303#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56303"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56303#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hualan Biological&#8217;s HL08 GLP-1 Drug Gets NMPA Nod for Obesity Trial"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56303","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56303"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56303\/revisions"}],"predecessor-version":[{"id":56306,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56303\/revisions\/56306"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56303"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56303"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56303"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}